DR Congo Ebola deaths surpass 3,000 as Bundibugyo outbreak spreads across six provinces

Scale of the epidemic

The Ebola epidemic in the Democratic Republic of the Congo has caused 3,007 deaths out of 6,186 confirmed cases, according to data collected by the National Institute of Public Health through 31 August 2026. The case fatality rate stands at 48.6%, with young children accounting for a disproportionately large share of fatalities. Health authorities recorded 1,409 recoveries, while 830 patients remain in isolation or specialised treatment centres. The outbreak is the deadliest in the country's history, surpassing the 2018–2020 epidemic that claimed nearly 2,300 lives among roughly 3,500 cases. Globally, the toll ranks second only to the 2014–2016 West African outbreak, which infected over 28,600 people and killed more than 11,000 across Guinea, Liberia and Sierra Leone.

Jean-Jacques Muyembe, a director at the Congolese Ministry of Health, described the operational challenge in an official statement.

The disease is spreading at an unprecedented speed, outstripping our efforts to track and contain it.

Spread and operational constraints

Originating in the north-eastern province of Ituri, where it was officially declared on 15 May 2026, the outbreak is active across 60 health zones in six provinces. In addition to Ituri, confirmed cases have been recorded in Tshopo, Bas-Uélé, Haut-Uélé, North Kivu and South Kivu, alongside cases detected across the border in Uganda. In North Kivu, where two additional health zones recently reported infections, mortality rates have been particularly steep, while South Kivu has recorded no new confirmed cases in more than 90 days. Containment efforts face armed conflict, persistent insecurity, attacks on health personnel, strikes by healthcare staff over unpaid wages, and high population mobility among miners. The World Health Organization estimates that roughly 60% of deaths occur outside specialised treatment centres, while Africa CDC indicated that weak surveillance means actual infections could be three times the official tally.

Vaccine rollout and clinical trials

The current outbreak is caused by the Bundibugyo species of the Ebola virus, for which no approved vaccine or specific therapy exists. To counter transmission, health authorities launched an immunisation drive using the Ervebo vaccine, originally licensed for the Zaire strain, after preliminary laboratory data suggested cross-protection. An initial shipment of 16,250 doses arrived in late August 2026, enabling vaccinations to begin in Kisangani, the capital of Tshopo province. Africa CDC outlined an allocation of 70,000 planned Ervebo doses, comprising 50,000 for healthcare staff and frontline responders, alongside 20,000 designated for a Phase 3 clinical trial evaluating its efficacy against Bundibugyo. In addition, two candidate vaccines have begun Phase 1 human safety trials, and clinical testing of two antiviral therapies has been underway since early July 2026.

International response and resources

Speaking in Geneva on 2 September 2026, World Health Organization Director-General Tedros Adhanom Ghebreyesus urged international donors to accelerate financing for the Congolese government's $1.3 billion response plan. The agency has deployed over 300 technical experts and delivered more than 330 tonnes of supplies, but additional funding is needed to expand bed capacity across treatment centres, where operating a single 1,500-bed facility costs $15 million per month. Tedros warned that many deceased individuals were omitted from contact-tracing registers, indicating unmonitored transmission chains compounded by unsafe burial customs.

Until every chain of transmission is found and broken, the epidemic will continue and remain a threat to the Democratic Republic of the Congo, its neighbours and the entire region.